Aim: To assess outcomes among patients with Duchenne muscular dystrophy receiving deflazacort or prednisone in real-world practice. Methods: Clinical data for 435 boys with Duchenne muscular dystrophy from Cincinnati Children's Hospital Medical Center were studied retrospectively using time-to-event and regression analyses. Results: Median ages at loss of ambulation were 15.6 and 13.5 years among deflazacort- and prednisone-initiated patients, respectively. Deflazacort was also associated with a lower risk of scoliosis and better ambulatory function, greater % lean body mass, shorter stature and lower weight, after adjusting for age and steroid duration. No differences were observed in whole body bone mineral density or left ventricular ejection fraction. Conclusion: This single center study adds to the real-world evidence associating deflazacort with improved clinical outcomes.
Keywords: Duchenne muscular dystrophy; deflazacort; prednisone; real-world data.
Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2016 May 5;(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149418 Review.
Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.Am J Phys Med Rehabil. 2005 Nov;84(11):843-50. doi: 10.1097/01.phm.0000184156.98671.d0. Am J Phys Med Rehabil. 2005. PMID: 16244521
Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.Neuromuscul Disord. 2004 Sep;14(8-9):476-82. doi: 10.1016/j.nmd.2004.05.001. Neuromuscul Disord. 2004. PMID: 15336688 Clinical Trial.
Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.J Pediatr. 2016 Jun;173:207-213.e3. doi: 10.1016/j.jpeds.2016.02.067. Epub 2016 Mar 30. J Pediatr. 2016. PMID: 27039228 Free PMC article.
Corticosteroids in Duchenne muscular dystrophy: a reappraisal.J Child Neurol. 2002 Mar;17(3):183-90. doi: 10.1177/088307380201700306. J Child Neurol. 2002. PMID: 12026233 Review.